COVID-19 vaccine in India may be ready by the year-end, says health minister

  • We are not lagging behind anyone else in the whole world in our efforts to contribute towards the vaccine against COVID, said health minister Harsh Vardhan

Written By Anulekha Ray
Updated31 Aug 2020, 03:33 PM IST
Health minister Harsh Vardhan said we hope to be able to get a vaccine against COVID by the end of this year.
Health minister Harsh Vardhan said we hope to be able to get a vaccine against COVID by the end of this year.

The whole world is waiting with bated breath for a 'safe and effective' vaccine against novel coronavirus. At present, three vaccine candidates are at different phases of trial in India. Two homegrown vaccine candidates — Covaxin by Bharat Biotech and ZyCoV-D by Zydus Cadila have already started the phase II clinical trial. Another vaccine candidate, Covishield, developed by the University of Oxford has recently commenced the phase II clinical trial in India. Vaccine maker AstraZeneca has signed a deal with Serum Institute of India to manufacture Oxford's COVID-19 vaccine candidate for India and low-income countries.

When will a COVID-19 vaccine be available in India? Answering to this question Union health and family welfare minister Dr Harsh Vardhan said that a vaccine might be ready by the end of this year.

"We are not lagging behind anyone else in the whole world in our efforts to contribute towards the vaccine against COVID... In India we have about 7-8 vaccine candidates, three of them in the clinical trial phases and rest in the pre- clinical trials and by the end of this year we hope to be able to get a vaccine against COVID," he said.

Here are key updates of India's COVID-19 vaccine journey

Covaxin, India's first coronavirus vaccine has been developed by Bharat Biotech developed by Bharat BioTech, Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). The clinical trial to verify the safety of potential COVID-19 vaccine has started in August.

"There had been 'no side effects' in the phase I trial of Covaxin," Dr E Venkata Rao, principal investigator of the trial at Institute of Medical Sciences and SUM Hospital, faculty of medical sciences, said.

ZyCoV-D, developed by Zydus Cadila began its phase II clinical trials from August 6. "The company reports that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, which began on July 15, 2020, has been well tolerated," Cadila Healthcare said.

"All the subjects in phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post dosing for safety and for 7 days thereafter and the vaccine was found to be very safe," Zydus Cadila Chairman Pankaj R Patel said.

Pune based drugmaker Serum Institute of India recently commenced the advance clinical trial of vaccine made by the University of Oxford. The vaccine maker has selected 17 sites across the country for the trial. Around 1,600 people between the age of 18 and 25 will be enrolled for the clinical trial.

"The volunteers do not have any pain, fever, injection-side reaction or systemic illness post-vaccination,"Dr Jitendra Oswal, deputy medical director, Bharti Vidyapeeth's Medical College and Hospital in Pune said.





Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:31 Aug 2020, 03:33 PM IST
Business NewsNewsIndiaCOVID-19 vaccine in India may be ready by the year-end, says health minister

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Tata Steel share price

    147.55
    03:59 PM | 8 NOV 2024
    -3.35 (-2.22%)

    Tata Motors share price

    805.70
    03:58 PM | 8 NOV 2024
    -14.1 (-1.72%)

    Indian Hotels Company share price

    733.05
    03:51 PM | 8 NOV 2024
    49.45 (7.23%)

    Ashok Leyland share price

    222.00
    03:59 PM | 8 NOV 2024
    6.2 (2.87%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Aarti Industries share price

    474.75
    03:59 PM | 8 NOV 2024
    -40.3 (-7.82%)

    Signatureglobal India share price

    1,274.45
    03:29 PM | 8 NOV 2024
    -107.95 (-7.81%)

    Great Eastern Shipping Company share price

    1,200.50
    03:29 PM | 8 NOV 2024
    -90.45 (-7.01%)

    GMM Pfaudler share price

    1,282.90
    03:29 PM | 8 NOV 2024
    -92 (-6.69%)
    More from Top Losers

    Indian Hotels Company share price

    733.05
    03:51 PM | 8 NOV 2024
    49.45 (7.23%)

    Vijaya Diagnostic Centre share price

    1,098.90
    03:29 PM | 8 NOV 2024
    71.45 (6.95%)

    Motilal Oswal Financial Services share price

    996.05
    03:59 PM | 8 NOV 2024
    61.85 (6.62%)

    One 97 Communications share price

    848.15
    03:58 PM | 8 NOV 2024
    52.35 (6.58%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      79,375.00-110.00
      Chennai
      79,381.00-110.00
      Delhi
      79,533.00-110.00
      Kolkata
      79,385.00-110.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L0.00
      Chennai
      100.80/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in News

        HomeMarketsPremiumInstant LoanMint Shorts